Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Tomas G Neilan, M.D.

Co-Author

This page shows the publications co-authored by Tomas Neilan and Leyre Zubiri.
Connection Strength

2.546
  1. Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors. Eur J Cancer. 2022 Mar; 163:108-118.
    View in: PubMed
    Score: 0.245
  2. Immune checkpoint inhibitors for cancer and venous thromboembolic events. Eur J Cancer. 2021 Oct 15; 158:99-110.
    View in: PubMed
    Score: 0.241
  3. Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. J Immunother Cancer. 2021 09; 9(9).
    View in: PubMed
    Score: 0.239
  4. Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. Immunother Adv. 2021 Jan; 1(1):ltab014.
    View in: PubMed
    Score: 0.236
  5. Pericardial disease in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021 06; 9(6).
    View in: PubMed
    Score: 0.235
  6. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. J Immunother Cancer. 2021 03; 9(3).
    View in: PubMed
    Score: 0.231
  7. Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor-Associated Myocarditis. J Am Heart Assoc. 2020 12; 9(23):e018306.
    View in: PubMed
    Score: 0.226
  8. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020 12 15; 142(24):2299-2311.
    View in: PubMed
    Score: 0.224
  9. Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. Circulation. 2020 06 16; 141(24):2031-2034.
    View in: PubMed
    Score: 0.220
  10. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2020 03; 25(3):e398-e404.
    View in: PubMed
    Score: 0.211
  11. Immune checkpoint inhibitor-induced thyroiditis is a risk factor for acute and chronic kidney dysfunction. Nephrol Dial Transplant. 2021 12 31; 37(1):187-189.
    View in: PubMed
    Score: 0.061
  12. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2021 07; 9(7).
    View in: PubMed
    Score: 0.059
  13. Incidence and Predictors of CKD and Estimated GFR Decline in Patients Receiving Immune Checkpoint Inhibitors. Am J Kidney Dis. 2022 01; 79(1):134-137.
    View in: PubMed
    Score: 0.059
  14. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist. 2021 06; 26(6):514-522.
    View in: PubMed
    Score: 0.058
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.